Key statistics
On Friday, Resmed Inc (RMD:NYQ) closed at 271.63, -7.55% below its 52-week high of 293.81, set on Aug 22, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 267.05 |
|---|---|
| High | 272.33 |
| Low | 267.03 |
| Bid | 263.00 |
| Offer | 274.12 |
| Previous close | 267.05 |
| Average volume | 1.49m |
|---|---|
| Shares outstanding | 145.68m |
| Free float | 144.94m |
| P/E (TTM) | 26.85 |
| Market cap | 39.57bn USD |
| EPS (TTM) | 10.12 USD |
| Annual div (ADY) | 2.40 USD |
|---|---|
| Annual div yield (ADY) | 0.90% |
| Div ex-date | Nov 13 2025 |
| Div pay-date | Dec 18 2025 |
| Next div ex-date | Feb 12 2026 |
| Next div pay-date | Mar 19 2026 |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
- Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026
- Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
- Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
- Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
- Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
- Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
- Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
- Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
- Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
More ▼
